Thrombosis News and Research

Latest Thrombosis News and Research

Cepheid receives approval to market Xpert(R) HemosIL(R) FII & FV test

Cepheid and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) HemosIL(R) FII & FV test.

25 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

Pre-clinical data demonstrates advantages of Combo Stent

OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Clinical study results of Novolimus and Myolimum eluting coronary stent systems released

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today positive results from three multicenter first-in-man studies of Novolimus and Myolimus eluting coronary stent systems with durable and bioabsorbable polymers. Findings were presented at the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT 2009) scientific symposium.

24 Sep 2009

COMPARE trial results demonstrate higher efficacy of XIENCE V stent system

Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS).

24 Sep 2009

SPIRIT IV trial data demonstrates superior efficacy of XIENCE V stent system

Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.

24 Sep 2009

New TAXUS Liberté Stent demonstrates superior results for treating long lesions

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has released comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS(R) Liberté(R) Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS(R) Express(R) Stent.

23 Sep 2009

Genous Bio-engineered R stent for STEMI implantation exhibits safety

OrbusNeich announced today that interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company's Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI).

23 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009

Winners of "Passion & Results" Award announced by Instrumentation Laboratory

Instrumentation Laboratory (IL) today announced the three recipients of their "Passion & Results" Award. The winners were presented with their awards by IL during ceremonies at the Congress for the International Society on Thrombosis and Haemostasis (ISTH) held in Boston, MA, July 11-16 and at the Annual Meeting for the American Association for Clinical Chemistry (AACC), in Chicago, IL, July 19-23.

22 Sep 2009

Transcatheter valve implantation is an effective treatment for patients with aortic stenosis

Research presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), demonstrated an "exceptionally low" rate of complications one year after implantation of transcatheter aortic valve prostheses.

22 Sep 2009

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS).

21 Sep 2009

Researchers find new technique for long-term treatment of DVT

Deep Venous Thrombosis (DVT) is a serious condition that involves the formation of a blood clot inside of a deep vein usually in the legs. A patient with DVT is typically treated with anticoagulants (blood thinners) however researchers have found that image-guided interventional radiology procedures may play a more central role in the long-term treatment of DVT, according to a study published in the October issue of the American Journal of Roentgenology (AJR).

21 Sep 2009

Four single-letter variations in SNPs increse prostate cancer risk

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer.

21 Sep 2009

New patent grant for oligonucleotide modulators of blood coagulation factor aptamers

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual property estate.

18 Sep 2009

Nutrient-rich powder from wine by-products

Two years ago, a group of friends were enjoying a glass of wine in the Mosel region in south-west Germany when their conversation turned to the health benefits which studies attribute to the drink.

18 Sep 2009

African Americans at higher risk of developing potentially deadly DVT and PE than other ethnic populations

Speaking at the Venous Disease Coalition (VDC) Annual Meeting today, Dr. Garth Graham from the Office of Minority Health at the Department of Health and Human Services followed up on last year's Surgeon General's Call to Action by focusing attention on the African American population which is at significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

18 Sep 2009

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

W. L. Gore & Associates (Gore) today announced that several physicians recently presented interim data from ongoing GORE PROPATEN® Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting. The conference, the premier event hosted by the Society for Vascular Surgery (SVS), was held in mid-June in Denver, Colorado. One physician reported primary patency rates as high as 100 percent for below-knee bypasses.

17 Sep 2009

Phase 3 clinical study results of bazedoxifene released

Wyeth Pharmaceuticals, a division of Wyeth, announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis.

15 Sep 2009

Thrombosis News and Research

Latest Thrombosis News and Research

Cepheid receives approval to market Xpert(R) HemosIL(R) FII & FV test

Everolimus-eluting stent efficient in treating native coronary artery lesions

Pre-clinical data demonstrates advantages of Combo Stent

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Clinical study results of Novolimus and Myolimum eluting coronary stent systems released

COMPARE trial results demonstrate higher efficacy of XIENCE V stent system

SPIRIT IV trial data demonstrates superior efficacy of XIENCE V stent system

New TAXUS Liberté Stent demonstrates superior results for treating long lesions

Genous Bio-engineered R stent for STEMI implantation exhibits safety

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Winners of "Passion & Results" Award announced by Instrumentation Laboratory

Transcatheter valve implantation is an effective treatment for patients with aortic stenosis

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Researchers find new technique for long-term treatment of DVT

Four single-letter variations in SNPs increse prostate cancer risk

New patent grant for oligonucleotide modulators of blood coagulation factor aptamers

Nutrient-rich powder from wine by-products

African Americans at higher risk of developing potentially deadly DVT and PE than other ethnic populations

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

Phase 3 clinical study results of bazedoxifene released

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Thrombosis News and Research

Latest Thrombosis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in